Roots Analysis has done a detailed study on “Oligonucleotide Synthesis, Modification and Purification Services Market: Focus on Research, Diagnostic and Therapeutic Applications, 2020-2030” covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
To order this 300+ page report, which features 140+ figures and 190+ tables, please visit this link Key Market InsightsMore than 80 companies currently claim to offer manufacturing related services, at different scales of operations, for a variety of oligonucleotide-based productsA wide range of services related to the synthesis, modification and purification of oligonucleotides, are currently offered within a fragmented service provider landscape that is mostly concentrated in the developed geographiesIn order to cater to the growing needs of clients / sponsors, companies have established presence across different regions; the US and some European nations have emerged as current hubs for oligonucleotide productionPlayers involved in this domain are steadily expanding their capabilities in order to enhance their respective service portfolios and thereby, achieve an edge over competing firmsService providers are actively investing in expansion projects to upgrade existing capabilities and capacity; several partnerships, mostly focused on offering manufacturing and supply services, have been forgedOver the past few years, more than 270 trials of oligonucleotide-based interventions, across various phases of development and to treat a diverse range of diseases, have been registered across different centers worldwideMost of the global, annual oligonucleotide manufacturing capacity belongs to established service providers, accounting for over 80% of available capacity across various geographiesThe demand for manufacturing of oligonucleotide-based products is expected to increase in the coming years; we believe that the stakeholders may have to expand their respective capacities to ensure consistent supplyWe expect oligonucleotide-based drug developers to continue to outsource their manufacturing operations in the short to mid-term; service-based revenues are estimated to grow at an annualized rate of more than 10%In the long-term, the projected opportunity is anticipated to be well distributed across various therapeutic areas, scales of operation and across companies of different sizes For more information, please visit https://www.rootsanalysis.com/reports/view_document/oligonucleotide-synthesis/304.html Table of Contents PREFACE1.1.
Analysis by Location of Manufacturing Facilities4.2.6.
Analysis by Regulatory Accreditations / Certifications4.2.7.
Oligonucleotide Manufacturing Market for Autoimmune Disorders, 2020-203015.4.2.4.2.
Interview Transcript: Tobias Pohlmann, Founder and Managing Director 18.3.
